Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 5, 2014, Pages 836-843

  Saint Aubert, L ^a   Nemmi, F ^a   Peran P ^a   Barbeau, E J ^a,b   Payoux, P ^a   Chollet, F ^a   Pariente, J ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b Brain and Cognition Research Center in Toulouse   (France)

Author keywords

Alzheimer's disease; Amyloid; Cortex; Florbetapir; PET imaging

Indexed keywords

FLORBETAPIR F 18; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; RADIOPHARMACEUTICAL AGENT;

AGED; ALZHEIMER DISEASE; ANTERIOR CINGULATE; ARTICLE; CLINICAL ARTICLE; CLINICAL RESEARCH; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; EFFECT SIZE; FEMALE; FRONTAL LOBE; GRAY MATTER; HUMAN; IMAGE PROCESSING; IN VIVO STUDY; INSULA; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PARIETAL LOBE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; RELIABILITY; TEMPORAL LOBE; WHITE MATTER; BRAIN CORTEX; CASE CONTROL STUDY; COMPARATIVE STUDY; DIAGNOSTIC USE; PROCEDURES; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; ANILINE COMPOUNDS; CASE-CONTROL STUDIES; CEREBRAL CORTEX; ETHYLENE GLYCOLS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84899118456     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2656-8     Document Type: Article

References (31)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-44.
2. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-9. doi: 10.1016/j.jalz.2011.03.005.
3. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734-46. doi: 10.1016/S1474-4422(07)70178-3.
4. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-19. doi: 10.1002/ana.20009.
5. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275-83. doi: 10.1001/jama.2010.2008.
6. Jack Jr CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131:665-80. doi: 10.1093/brain/awm336.
7. Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain. 2011;134:1077-88. doi: 10.1093/brain/awr044.
8. Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404-11. doi: 10.1001/archneurol.2011.150.
9. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913-20. doi: 10.2967/jnumed.109.069088.
10. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275-83. doi: 10.1016/j.neurobiolaging.2010.04.007.
11. Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9(5 Suppl):S72-83. doi: 10.1016/j.jalz.2012.10.007.
12. Saint-Aubert L, Barbeau EJ, Peran P, Nemmi F, Vervueren C, Mirabel H, et al. Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients. EJNMMI Res. 2013;3:43. doi: 10.1186/2191-219X-3-43.
13. Saint-Aubert L, Planton M, Hannequin D, Albucher JF, Delisle MB, Payoux P, et al. Amyloid imaging with AV45 ((18)F-florbetapir) in a cognitively normal AbetaPP duplication carrier. J Alzheimers Dis. 2012;28:877-83. doi: 10.3233/JAD-2011-111598.
14. FDA approves 18F-florbetapir PET agent. J Nucl Med. 2012;53:15N. doi:53/6/15N [pii]
15. Booij J, Arbizu J, Darcourt J, Hesse S, Nobili F, Payoux P, et al. Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2013;40:1122-5. doi: 10.1007/s00259-013-2415-x.
16. Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83:923-6. doi: 10.1136/jnnp-2012-302548.
17. La Joie R, Perrotin A, Barre L, Hommet C, Mezenge F, Ibazizene M, et al. Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia. J Neurosci. 2012;32:16265-73. doi: 10.1523/JNEUROSCI.2170-12.2012.
18. Rodrigue KM, Kennedy KM, Devous Sr MD, Rieck JR, Hebrank AC, Diaz-Arrastia R, et al. beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78:387-95. doi: 10.1212/WNL.0b013e318245d295.
19. Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology. 2007;69:1859-67. doi: 10.1212/01.wnl.0000279336. 36610.f7.
20. Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem. 2007;101:1053-9. doi: 10.1111/j.1471-4159.2006.04404.x.
21. Wallon D, Rousseau S, Rovelet-Lecrux A, Quillard-Muraine M, Guyant-Marechal L, Martinaud O, et al. The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis. 2012;30:847-56. doi: 10.3233/JAD-2012-120172.
22. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17:825-41.
23. Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent - a pilot study. Nucl Med Biol. 2010;37:497-508. doi: 10.1016/j.nucmedbio. 2010.02.003.
24. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273-89. doi: 10.1006/nimg.2001.0978.
25. Edison P, Carter SF, Rinne JO, Gelosa G, Herholz K, Nordberg A, et al. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. Neuroimage. 2013;70:423-33. doi: 10.1016/j.neuroimage.2012.12.014.
26. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988
27. Zakzanis KK. Statistics to tell the truth, the whole truth, and nothing but the truth: formulae, illustrative numerical examples, and heuristic interpretation of effect size analyses for neuropsychological researchers. Arch Clin Neuropsychol. 2001;16:653-67.
28. Camus V, Payoux P, Barre L, Desgranges B, Voisin T, Tauber C, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012;39:621-31. doi: 10.1007/s00259-011-2021-8.
29. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70-7. doi: 10.2967/jnumed.112.109009.
30. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79:1636-44. doi: 10.1212/WNL.0b013e3182661f74.
31. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446-52. doi: 10.1212/01.wnl.0000228230.26044.a4.